Clinicopathological Significance of Long Non-Coding RNA GHET1 in Human cancers: A Meta-Analysis

INTRODUCTION Cancer is considered as the main public health problem and the second leading cause of morbidity and mortality worldwide. Numerous environmental-lifestyle related risk factors account for around one-third of cancer deaths. Recently, the key role of lncRNAs has been widely investigated in a variety of disorders including cancer. the lncRNA GHET1, has been considered as an essential oncogenic lncRNA in many types of human cancers. Clinical investi-gations indicated that expression of lncRNA GHET1 is correlated with clinicopathological characteristics in cancer. this me-ta-analysis investigated the correlation between the lncRNA GHET1 expression and clinicopathological features in different types of cancers. MATERIALS AND METHODS Comprehensive literature search in PubMed, Scopus, and Web of Knowledge were conducted up to April 11, 2019. sixteen studies were included in this meta-analysis. All statistical analyses were conducted using Stata soft-ware, version 12.0. RESULTS The pooled OR and 95%CIs of the sixteen relevant studies showed that over expression of lncRNA GHET1 was associated with tumor-size ≥5 cm (OR= 2.51, 95%CI: 1.89-3.33, p=0.00, I2=38.30%), positive lymph node metastasis (OR= 2.83, 95%CI: 1.78-4.52, p=0.00, I2=45.60%), advanced tumor stage (OR= 3.92, 95%CI: 2.97-5.19, p=0.00, I2=0.00%), positive distant metastasis (OR= 5.74, 95%CI: 2.58-12.77, p=0.00, I2=0.00%), advanced tumor status (OR= 2.97, 95%CI: 1.40-6.29, p=0.01, I2=34.70%), and positive vascular invasion (OR= 2.69, 95%CI: 1.61-4.50, p=0.00, I2=29.20%). CONCLUSION Taken together, the current study demonstrated that overexpression of lncRNA GHET1 is significantly associ-ated with clinicopathological features in human cancers. Our results suggested that lncRNA GHET1 can be utilized as a prognostic biomarker in human cancer.